Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with
resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However …

The advent of immune checkpoint blockade has revolutionized the management of
advanced non-small cell lung cancer (NSCLC). Impressive results in the metastatic setting …

Background In recent years, a series of clinical trials have explored the application of
neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer …

Multimodality treatment provides modest survival benefits for patients with locally advanced
(stage III) non-small-cell lung cancer (NSCLC). Nevertheless, preoperative immunotherapy …

Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …

Objectives Pembrolizumab is a programmed death receptor-1 masking antibody approved
for metastatic non–small cell lung cancer. This Phase 2 study (NCT02818920) of …